Aprea Therapeutics’ (APRE) Outperform Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research report released on Tuesday,RTT News reports. Wedbush currently has a $11.00 price target on the stock. Wedbush also issued estimates for Aprea Therapeutics’ FY2029 earnings at $2.19 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $2.20 on Tuesday. The company’s 50 day simple moving average is $3.06 and its two-hundred day simple moving average is $3.24. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $6.80. The stock has a market capitalization of $11.96 million, a PE ratio of -0.78 and a beta of 0.82.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.20. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, research analysts anticipate that Aprea Therapeutics will post -2.55 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

Institutional investors have recently made changes to their positions in the stock. Landscape Capital Management L.L.C. bought a new stake in shares of Aprea Therapeutics during the 4th quarter worth $116,000. LPL Financial LLC bought a new stake in Aprea Therapeutics during the fourth quarter worth about $53,000. BNP Paribas Financial Markets bought a new stake in Aprea Therapeutics during the fourth quarter worth about $43,000. Finally, Stonepine Capital Management LLC boosted its holdings in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares in the last quarter. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.